Publications by authors named "Mahrukh M Hussain"
Background: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced-stage epithelial ovarian cancer (EOC) who were receiving dose-intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing schedule.
Methods: Patients with stage III/IV EOC received cyclophosphamide 750 mg/m(2), followed by a 24-hour infusion of paclitaxel 250 mg/m(2) and cisplatin 75 mg/m(2) on Day 2. Filgrastim began on Day 3 at 10 microg/kg daily for 9 days.
Background: c-Kit and platelet-derived growth factor receptor (PDGFR) are potential molecular targets in epithelial ovarian cancer (EOC). Imatinib inhibits the kinase domain and subsequent downstream signaling of these receptor tyrosine kinases. The objective of this study was to investigate biochemical and biologic effects of imatinib on EOC.
View Article and Find Full Text PDFBackground: The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal-transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and determining the association between biochemical and clinical outcomes.
Methods: Twenty-four heavily pretreated patients with EOC who had good end-organ function and performance status and who had measurable disease received gefitinib 500 mg daily.
Article Synopsis
- Carboxyamidotriazole (CAI) is a drug that inhibits certain calcium channels, aiming to stop tumor growth and metastasis, and was tested for its effectiveness in stabilizing relapsed ovarian cancer for at least 6 months.
- In the study, patients with measurable ovarian cancer were given daily doses of CAI while monitoring its effects through imaging every 8 weeks, with mixed results on disease stabilization.
- Out of 36 patients evaluated, 31% achieved the desired outcome of disease stabilization for 6 months, and CAI showed a manageable toxicity profile, making it a candidate for further research in ovarian cancer treatment.